Neurocrine Biosciences INC (NBIX) Holder Fosun International LTD Has Increased Its Holding by $3.32 Million as Stock Rose

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) LogoInvestors sentiment increased to 1.44 in 2019 Q1. Its up 0.45, from 0.99 in 2018Q4. It increased, as 37 investors sold NBIX shares while 71 reduced holdings. 45 funds opened positions while 110 raised stakes. 101.77 million shares or 17.27% more from 86.79 million shares in 2018Q4 were reported. Cubist Systematic Strategies Limited Liability Corp has invested 0.04% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Stifel Finance Corporation holds 0% or 3,833 shares. 2,700 are held by Quantitative Investment Mgmt. Bb Biotech Ag holds 7.46% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 3.37 million shares. Shanda Asset Mgmt holds 0.14% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 10,000 shares. Pnc Fincl Services Group Inc Inc holds 1,025 shares. Aperio Grp Inc owns 28,100 shares or 0.01% of their US portfolio. Braun Stacey holds 0.45% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 76,527 shares. Mackay Shields Lc invested in 0.16% or 16.86 million shares. Cwm Limited Liability Corp invested in 0% or 18 shares. The New York-based Neuberger Berman Group Limited Liability Com has invested 0.01% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Northwestern Mutual Wealth Mgmt invested in 86 shares. Deutsche Bancorp Ag owns 1.02 million shares for 0.05% of their portfolio. Van Eck Assoc invested in 113,766 shares. Sumitomo Mitsui Asset Mgmt Limited has invested 0.01% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Fosun International Ltd increased its stake in Neurocrine Biosciences Inc (NBIX) by 62.58% based on its latest 2019Q1 regulatory filing with the SEC. Fosun International Ltd bought 39,000 shares as the company’s stock rose 29.28% . The institutional investor held 101,323 shares of the health care company at the end of 2019Q1, valued at $8.67M, up from 62,323 at the end of the previous reported quarter. Fosun International Ltd who had been investing in Neurocrine Biosciences Inc for a number of months, seems to be bullish on the $8.69 billion market cap company. The stock increased 0.53% or $0.5 during the last trading session, reaching $94.88. About 483,284 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has declined 2.64% since August 15, 2018 and is downtrending. It has underperformed by 2.64% the S&P500.

Fosun International Ltd, which manages about $1.57 billion US Long portfolio, decreased its stake in Cowen Inc by 429,940 shares to 92,221 shares, valued at $1.34M in 2019Q1, according to the filing. It also reduced its holding in Vipshop Hldgs Ltd (NYSE:VIPS) by 6.67M shares in the quarter, leaving it with 1.04 million shares, and cut its stake in Brookdale Sr Living Inc (NYSE:BKD).

More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: Nasdaq.com which released: “Why Neurocrine (NBIX) Could Be Positioned for a Surge – Nasdaq” on August 14, 2019, also Nasdaq.com with their article: “Moving Average Crossover Alert: Neurocrine Biosciences – Nasdaq” published on August 13, 2019, Nasdaq.com published: “First Week of April 18th Options Trading For Neurocrine Biosciences (NBIX) – Nasdaq” on March 07, 2019. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: Nasdaq.com and their article: “Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? – Nasdaq” published on July 22, 2019 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 07/30/2019: MEDP,NBIX,HCA – Nasdaq” with publication date: July 30, 2019.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 8 analysts covering Neurocrine (NASDAQ:NBIX), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Neurocrine has $127 highest and $87 lowest target. $108.25’s average target is 14.09% above currents $94.88 stock price. Neurocrine had 15 analyst reports since March 12, 2019 according to SRatingsIntel. H.C. Wainwright maintained the shares of NBIX in report on Wednesday, March 13 with “Buy” rating. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Hold” rating given on Tuesday, March 12 by Leerink Swann. The rating was maintained by Piper Jaffray with “Overweight” on Tuesday, July 30. Cantor Fitzgerald maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Tuesday, March 12 with “Buy” rating. JP Morgan upgraded Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Monday, April 22. JP Morgan has “Overweight” rating and $106 target. The rating was maintained by Cowen & Co with “Buy” on Wednesday, March 13. Credit Suisse maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Tuesday, July 30 with “Outperform” rating.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.